Surprise! Pfizer jumps the queue and leaps into RSV vax contention as COVID helps turbo charge work

Watch out, GlaxoSmithKline and Johnson & Johnson, Pfizer is steaming into the respiratory syncytial virus (RSV) vaccine race in what looks like a late break that could soon become gold.

In data dropped rather quietly during second-quarter earnings this week and to little fanfare, Pfizer said a challenge study, where vaccines were given to 62 adults under 50 who were then intentionally infected with RSV to see if the shot worked, showed “100% observed efficacy against mild to moderate symptomatic infection resulting from RSV.”